drugset / Trial / NCT01183559

A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery

NCT01183559

Phase 1 Completed 9 enrolled Fox Chase Cancer Center AstraZeneca · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to determine the most tolerable and safe dose of ZD6474 (Zactima, Vandetanib) when given with standard chemotherapy, radiation therapy and surgery in patients with cancer of the esophagus

Timeline

Start
2008-08-07
Primary completion
2010-11
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Vandetanib Small molecule 100 mg Oral
Subject Vandetanib Small molecule 200 mg Oral
Background Carboplatin Small molecule
Background Paclitaxel Small molecule 50 mg/m2 Intravenous
Background fluorouracil Small molecule 225 mg/m2